🇺🇸 FDA
Pipeline program

Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

INS1009-311

Phase 3 small_molecule active

Quick answer

Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER for Pulmonary Hypertension Associated with Interstitial Lung Disease is a Phase 3 program (small_molecule) at Insmed Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Insmed Limited
Indication
Pulmonary Hypertension Associated with Interstitial Lung Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials